Calcium Channel Blocker Market by Drug class (Dihydropyridine and Non-Dihydropyridine) for Hypertension, Angina Pectoris, Pregnancy, Obesity and Forecast, 2016 – 2022 – A to Z Research – Market Research Reports, Industry Research & Consulting Services

Calcium Channel Blocker Market by Drug class (Dihydropyridine and Non-Dihydropyridine) for Hypertension, Angina Pectoris, Pregnancy, Obesity and Forecast, 2016 – 2022

November 2, 2017

Comments Off

According to the report, the global calcium channel blocker market accounted for USD 11.26 billion in 2016 and is expected to reach USD 15.31 billion, growing at a CAGR of around 5.4% between 2017 and 2022.Calcium channel blockers are the chemical class of antihypertensive drugs used to treat various ill conditions of the heart and blood vessels. For example, CCB is commonly used in the treatment of angina pectoris, hypertension, and Reynaud’s phenomenon. Combination therapy is commonly used in the treatment of high blood pressure or angina pectoris.

[wptab name=’Report Description’ active=”1″ ]

Calcium channel blockers (CCBs) or calcium antagonists are among the most widely used drugs in cardiovascular medicine. CCBs promote vasodilator activity and thus act by reducing calcium influx into vascular smooth muscle cells by interfering with voltage-operated calcium channels in the cell membrane. This activity of calcium channel blockers helps for treating Hypertension and various other cardiovascular diseases.

The market of global calcium channel blocker has been accelerated by rising prevalence of hypertension across the globe. Moreover, calcium channel blockers are an essential class of cardiovascular drug prescribed by a physician for the treatment of hypertension which helps in propelling the growth of calcium channel blocker market. Furthermore, its wide application in pharmaceutical industry is expected to fuel the growth of global calcium channel blocker market. As well, the rising percentage of the obese population is also considered as a major driving factor for the growth of CCB market. However, availability of alternatives and certain side effect of CCB can restrict the growth of calcium channel blocker market. Nonetheless, ongoing research and development and combination therapy will serve as major opportunities for upcoming growth of calcium channel blocker market.

Based on product, calcium channel blocker market segmented into two types: Dihydropyridine and Non-Dihydropyridine. Dihydropyridine market is further sub-segmented into Amlodipine, Cilnidipine, Felodipine, Verapamil, Diltiazem, Isradipine, Nicardipine, Nisoldipine, Nifedipine and others. In 2016, amlodipine held the largest market share in terms of total revenue generation in the Dihydropyridine market. This growth is attributed due to the most preference by the physician or consultant towards amlodipine over the other drugs.

Based on application, calcium channel blocker market segmented into five types: hypertension, angina pectoris, pregnancy, anti-obesity and other. Hypertension dominated the calcium channel blockers market in 2016. This segment accounted for the largest market share in term of revenue generation in 2016. The growth of hypertension market is attributed due to large hypertension patient population than any other illness which can be treated by CCB.

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global calcium channel blocker include Pfizer Inc., AstraZeneca plc., bayer healthcare llc., GlaxoSmithKline plc., Sanofi S.A., Johnson & Johnson, Abcam, AbMole Bioscience, and Clearsynth.

[/wptab]

[wptab name=’Table of content’]

Chapter 1. Introduction
- 1.1. Report Description And Scope
- 1.2. Research Scope
- 1.3. Research Methodology
  - 1.3.1. Market Research Process
  - 1.3.2. Market Research Methodology
Chapter 2. Executive Summary
- 2.1. Global Calcium Channel Blocker Market, 2016 – 2022 (USD Million)
- 2.2. Global Calcium Channel Blocker Market: Snapshot
Chapter 3. Calcium Channel Blocker – Market Dynamics
- 3.1. Introduction
- 3.2. Value Chain Analysis
- 3.3. Market Drivers
  - 3.3.1. Global Calcium Channel Blocker Market Drivers: Impact Analysis
  - 3.3.2. Rising prevalence of Hypertension.
  - 3.3.3. Growth percentage of Obesity.
- 3.4. Market Restraints
  - 3.4.1. Global Calcium Channel Blocker Market Restraints: Impact Analysis
  - 3.4.2. Adverse Effect of Drug.
- 3.5. Opportunities
  - 3.5.1. Combination Therapy of CCB Drugs
- 3.6. Porter’s Five Forces Analysis
  - 3.6.1. Bargaining Power Of Suppliers
  - 3.6.2. Bargaining Power Of Buyers
  - 3.6.3. Threat From New Entrants
  - 3.6.4. Threat From New Substitutes
  - 3.6.5. Degree Of Competition
- 3.7. Market Attractiveness Analysis
  - 3.7.1. Market Attractiveness Analysis, By Drug Class Segment
  - 3.7.2. Market Attractiveness Analysis, By Application Segment
  - 3.7.3. Market Attractiveness Analysis, By Regional Segment
Chapter 4. Global Calcium Channel Blocker Market – Competitive Landscape
- 4.1. Company Market Share, 2016 (Subject To Data Availability)
- 4.2. Strategic Development
  - 4.2.1. Acquisitions & Mergers
  - 4.2.2. New Product Launch
  - 4.2.3. Agreements, Partnerships, Collaborations And Joint Ventures
  - 4.2.4. Research And Development, Product And Regional Expansion
- 4.3. Product Portfolio
Chapter 5. Global Calcium Channel Blocker Market – Drug Class Segment Analysis
- 5.1. Global Calcium Channel Blocker Market: Drug Class Segment Overview
  - 5.1.1. Global Calcium Channel Blocker Market Revenue Share, By Drug Class Segment, 2016 And 2022
- 5.2. Dihydropyridine
  - 5.2.1. Global Dihydropyridine Market, 2016 – 2022 (USD Million)
  - 5.2.2. Amlodipine
    - 5.2.2.1. Calcium Channel Blocker Market Revenue for Amlodipine , 2016 – 2022 (USD Million)
  - 5.2.3. Cilnidipine
    - 5.2.3.1. Calcium Channel Blocker Market Revenue for Cilnidipine , 2016 – 2022 (USD Million)
  - 5.2.4. Felodipine
    - 5.2.4.1. Calcium Channel Blocker Market Revenue for Felodipine , 2016 – 2022 (USD Million)
  - 5.2.5. Isradipine
    - 5.2.5.1. Calcium Channel Blocker Market Revenue for Isradipine , 2016 – 2022 (USD Million)
  - 5.2.6. Nicardipine
    - 5.2.6.1. Calcium Channel Blocker Market Revenue for Nicardipine , 2016 – 2022 (USD Million)
  - 5.2.7. Nisoldipine
    - 5.2.7.1. Calcium Channel Blocker Market Revenue for Nisoldipine , 2016 – 2022 (USD Million)
  - 5.2.8. Nifedipine
    - 5.2.8.1. Calcium Channel Blocker Market Revenue for Nifedipine , 2016 – 2022 (USD Million)
  - 5.2.9. Others
    - 5.2.9.1. Calcium Channel Blocker Market Revenue for Others , 2016 – 2022 (USD Million)
- 5.3. Non-Dihydropyridine
  - 5.3.1. Global Non-Dihydropyridine Market, 2016 – 2022 (USD Million)
  - 5.3.2. Diltiazem
    - 5.3.2.1. Calcium Channel Blocker Market Revenue for Diltiazem , 2016 – 2022 (USD Million)
  - 5.3.3. Verapamil
    - 5.3.3.1. Calcium Channel Blocker Market Revenue for Verapamil , 2016 – 2022 (USD Million)
Chapter 6. Global Calcium Channel Blocker Market – Application Segment Analysis
- 6.1. Global Calcium Channel Blocker Market: Application Segment Overview
  - 6.1.1. Global Calcium Channel Blocker Market Revenue Share, By Application Segment, 2016 And 2022
- 6.2. Angina Pectoris
  - 6.2.1. Global Calcium Channel Blocker Market For Angina Pectoris, 2016 – 2022 (USD Million)
- 6.3. Hypertension
  - 6.3.1. Global Calcium Channel Blocker Market For Hypertension, 2016 – 2022 (USD Million)
- 6.4. Pregnancy
  - 6.4.1. Global Calcium Channel Blocker Market For Pregnancy, 2016 – 2022 (USD Million)
- 6.5. Obesity
  - 6.5.1. Global Calcium Channel Blocker Market For Obesity, 2016 – 2022 (USD Million)
- 6.6. Others
  - 6.6.1. Global Calcium Channel Blocker Market For Others, 2016 – 2022 (USD Million)
Chapter 7. Global Calcium Channel Blocker Market – Regional Segment Analysis
- 7.1. Global Calcium Channel Blocker Market: Regional Overview
  - 7.1.1. Global Calcium Channel Blocker Market Revenue Share, By Region, 2016 And 2022
- 7.2. North America
  - 7.2.1. North America Calcium Channel Blocker Market Revenue, By Drug Class , 2016 – 2022 , (USD Million)
  - 7.2.2. North America Calcium Channel Blocker Market Revenue, By Application, 2016 – 2022 , (USD Million)
- 7.3. Europe
  - 7.3.1. Europe Calcium Channel Blocker Market Revenue, By Drug Class , 2016 – 2022 (USD Million)
  - 7.3.2. Europe Calcium Channel Blocker Market Revenue, By Application, 2016 – 2022 (USD Million)
- 7.4. Asia Pacific
  - 7.4.1. Asia Pacific Calcium Channel Blocker Market Revenue, By Drug Class , 2016 – 2022 (USD Million)
  - 7.4.2. Asia Pacific Calcium Channel Blocker Market Revenue, By Application, 2016 – 2022 (USD Million)
- 7.5. Latin America
  - 7.5.1. Latin America Calcium Channel Blocker Market Revenue, By Drug Class , 2016 – 2022 (USD Million)
  - 7.5.2. Latin America Calcium Channel Blocker Market Revenue, By Application, 2016 – 2022 (USD Million)
- 7.6. Middle East And Africa
  - 7.6.1. Middle East And Africa Calcium Channel Blocker Market Revenue, By Drug Class , 2016 – 2022 (USD Million)
  - 7.6.2. Middle East And Africa Calcium Channel Blocker Market Revenue, By Application, 2016 – 2022 (USD Million)
Chapter 8. Company Profile
- 8.1. Pfizer Inc.,
  - 8.1.1. Overview
  - 8.1.2. Financials
  - 8.1.3. Product Portfolio
  - 8.1.4. Business Strategy
  - 8.1.5. Recent Developments
- 8.2. AstraZeneca plc.,
  - 8.2.1. Overview
  - 8.2.2. Financials
  - 8.2.3. Product Portfolio
  - 8.2.4. Business Strategy
  - 8.2.5. Recent Developments
- 8.3. Bayer Healthcare LLC.
  - 8.3.1. Overview
  - 8.3.2. Financials
  - 8.3.3. Product Portfolio
  - 8.3.4. Business Strategy
  - 8.3.5. Recent Developments
- 8.4. GlaxoSmithKline plc
  - 8.4.1. Overview
  - 8.4.2. Financials
  - 8.4.3. Product Portfolio
  - 8.4.4. Business Strategy
  - 8.4.5. Recent Developments
- 8.5. Sanofi S.A.
  - 8.5.1. Overview
  - 8.5.2. Financials
  - 8.5.3. Product Portfolio
  - 8.5.4. Business Strategy
  - 8.5.5. Recent Developments
- 8.6. Johnson & Johnson
  - 8.6.1. Overview
  - 8.6.2. Financials
  - 8.6.3. Product Portfolio
  - 8.6.4. Business Strategy
  - 8.6.5. Recent Developments
- 8.7. Abcam
  - 8.7.1. Overview
  - 8.7.2. Financials
  - 8.7.3. Product Portfolio
  - 8.7.4. Business Strategy
  - 8.7.5. Recent Developments
- 8.8. AbMole Bioscience
  - 8.8.1. Overview
  - 8.8.2. Financials
  - 8.8.3. Product Portfolio
  - 8.8.4. Business Strategy
  - 8.8.5. Recent Developments
- 8.9. Clearsynth
  - 8.9.1. Overview
  - 8.9.2. Financials
  - 8.9.3. Product Portfolio
  - 8.9.4. Business Strategy
  - 8.9.5. Recent Developments

List of Figures

1. Market Research Process
2. Market Research Methodology
3. Global Calcium Channel Blocker Market Revenue, 2016 – 2022 (USD Million)
4. Porter’s Five Forces Analysis
5. Calcium Channel Blocker: Market Attractiveness Analysis, By Drug Class Segment
6. Calcium Channel Blocker: Market Attractiveness Analysis, By Application Segment
7. Calcium Channel Blocker: Market Attractiveness Analysis, By Regional Segment
8. Company Market Share Analysis, 2016 And 2022
9. Global Calcium Channel Blocker Market Revenue Share By Drug Class, 2016 And 2022
10. Calcium Channel Blocker Market For Dihydropyridine, 2016 – 2022, (USD Million)
11. Calcium Channel Blocker Market For Amlodipine, 2016 – 2022, (USD Million)
12. Calcium Channel Blocker Market For Cilnidipine, 2016 – 2022, (USD Million)
13. Calcium Channel Blocker Market For Felodipine, 2016 – 2022, (USD Million)
14. Calcium Channel Blocker Market For Isradipine, 2016 – 2022, (USD Million)
15. Calcium Channel Blocker Market For Nicardipine, 2016 – 2022, (USD Million)
16. Calcium Channel Blocker Market For Nisoldipine, 2016 – 2022, (USD Million)
17. Calcium Channel Blocker Market For Nifedipine, 2016 – 2022, (USD Million)
18. Calcium Channel Blocker Market For Others, 2016 – 2022, (USD Million)
19. Calcium Channel Blocker Market For Non-Dihydropyridine, 2016 – 2022, (USD Million)
20. Calcium Channel Blocker Market For Diltiazem, 2016 – 2022, (USD Million)
21. Calcium Channel Blocker Market For Verapamil, 2016 – 2022, (USD Million)
22. Global Calcium Channel Blocker Market Revenue Share By Application, 2016 And 2022
23. Calcium Channel Blocker Market For Angina Pectoris, 2016 – 2022, (USD Million)
24. Calcium Channel Blocker Market For Hypertension, 2016 – 2022, (USD Million)
25. Calcium Channel Blocker Market For Pregnancy, 2016 – 2022, (USD Million)
26. Calcium Channel Blocker Market For Obesity, 2016 – 2022, (USD Million)
27. Calcium Channel Blocker Market For Others, 2016 – 2022, (USD Million)
28. Global Calcium Channel Blocker Market Share, By Region, 2016 – 2022
29. North America Calcium Channel Blocker Market, 2016 – 2022, (USD Million)
30. U.S. Calcium Channel Blocker Market, 2016 – 2022, (USD Million)
31. Europe Calcium Channel Blocker Market, 2016 – 2022, (USD Million)
32. Asia Pacific Calcium Channel Blocker Market, 2016 – 2022, (USD Million)
33. China Calcium Channel Blocker Market, 2016 – 2022, (USD Million)
34. Japan Calcium Channel Blocker Market, 2016 – 2022, (USD Million)
35. Latin America Calcium Channel Blocker Market, 2016-2022, (USD Million)
36. Brazil Calcium Channel Blocker Market, 2016 – 2022, (USD Million)
37. Middle East & Africa Calcium Channel Blocker Market, 2016 – 2022, (USD Million)

List of Tables

1. Calcium Channel Blocker Market: Market Snapshot
2. Drivers Of Global Calcium Channel Blocker Market: Impact Analysis
3. Restraints Of Global Calcium Channel Blocker Market: Impact Analysis
4. North America Calcium Channel Blocker Market Revenue, By Drug Class , 2016 – 2022(USD Million)
5. North America Calcium Channel Blocker Market Revenue, By Application, 2016 – 2022(USD Million)
6. U.S. Calcium Channel Blocker Market Revenue, By Drug Class , 2016 – 2022(USD Million)
7. U.S. Calcium Channel Blocker Market Revenue, By Application, 2016 – 2022(USD Million)
8. Europe Calcium Channel Blocker Market Revenue, By Drug Class , 2016 – 2022(USD Million)
9. Europe Calcium Channel Blocker Market Revenue, By Application, 2016 – 2022(USD Million)
10. Asia Pacific Calcium Channel Blocker Market Revenue, By Drug Class 2016 – 2022(USD Million)
11. Asia Pacific Calcium Channel Blocker Market Revenue, By Application 2016 – 2022(USD Million)
12. Japan Calcium Channel Blocker Market Revenue, By Drug Class , 2016 – 2022(USD Million)
13. Japan Calcium Channel Blocker Market Revenue, By Application, 2016 – 2022(USD Million)
14. India Calcium Channel Blocker Market Revenue, By Drug Class , 2016 – 2022(USD Million)
15. India Calcium Channel Blocker Market Revenue, By Application, 2016 – 2022(USD Million)
16. Latin America Calcium Channel Blocker Market Revenue, By Drug Class – 2016 – 2022 (USD Million)
17. Latin America Calcium Channel Blocker Market Revenue, By Application – 2016 – 2022 (USD Million)
18. Brazil Calcium Channel Blocker Market Revenue, By Drug Class , 2016 – 2022(USD Million)
19. Brazil Calcium Channel Blocker Market Revenue, By Application, 2016 – 2022(USD Million)
20. Middle East And Africa Calcium Channel Blocker Market Revenue, By Drug Class 2016 – 2022 (USD Million)
21. Middle East And Africa Calcium Channel Blocker Market Revenue, By Application 2016 – 2022 (USD Million)

[/wptab]

[wptab name=’Request For Sample’]

[contact-form-7 id=”7″ title=”Request For Sample”]

[/wptab]

[end_wptabset]

A to Z Research – Market Research Reports, Industry Research & Consulting Services

Calcium Channel Blocker Market by Drug class (Dihydropyridine and Non-Dihydropyridine) for Hypertension, Angina Pectoris, Pregnancy, Obesity and Forecast, 2016 – 2022